<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nalidixic acid, the <z:chebi fb="1" ids="23765">quinolone</z:chebi> frequently used in the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0013369" disease_type="Disease or Syndrome" abbrv="">dysentery</z:e>, is now emerging as an important cause of <z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">pseudotumour cerebri</z:e> in infants and young children </plain></SENT>
<SENT sid="1" pm="."><plain>A study of 20 such cases showed that <z:hpo ids='HP_0000001'>all</z:hpo> the patients had received a higher than recommended dose of nalidixic acid and that 85% of them were given the drug unnecessarily (i.e., for <z:hpo ids='HP_0011009'>acute</z:hpo> watery diarrhoea) </plain></SENT>
<SENT sid="2" pm="."><plain>A high concentration of the drug in the commercial preparations as well as the lack of awareness about this among doctors, especially the general practitioners, is the possible contributory factor leading to this situation </plain></SENT>
<SENT sid="3" pm="."><plain>A simple measure of bringing down the concentration of nalidixic acid in the available preparations and sticking to oral rehydration solution alone in the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> watery diarrhoea, can bring down the incidence of this condition </plain></SENT>
</text></document>